Pharmacogenetics of novel glucose-lowering drugs
- PMID: 33594477
- PMCID: PMC8099830
- DOI: 10.1007/s00125-021-05402-w
Pharmacogenetics of novel glucose-lowering drugs
Abstract
The aim of this work was to review studies in which genetic variants were assessed with respect to metabolic response to treatment with novel glucose-lowering drugs: dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i). In total, 22 studies were retrieved from the literature (MEDLINE). Variants of the GLP-1 receptor gene (GLP1R) were associated with a smaller reduction in HbA1c in response to DPP-4i. Variants of a number of other genes (KCNQ1, KCNJ11, CTRB1/2, PRKD1, CDKAL1, IL6 promoter region, TCF7L2, DPP4, PNPLA3) have also been related to DPP-4i response, although replication studies are lacking. The GLP1R gene was also reported to play a role in the response to GLP-1 RA, with larger weight reductions being reported in carriers of GLP1R variant alleles. There were variants of a few other genes (CNR1, TCF7L2, SORCS1) described to be related to GLP-1 RA. For SGLT2i, studies have focused on genes affecting renal glucose reabsorption (e.g. SLC5A2) but no relationship between SLC5A2 variants and response to empagliflozin has been found. The relevance of the included studies is limited due to small genetic effects, low sample sizes, limited statistical power, inadequate statistics (lack of gene-drug interactions), inadequate accounting for confounders and effects modifiers, and a lack of replication studies. Most studies have been based on candidate genes. Genome-wide association studies, in that respect, may be a more promising approach to providing novel insights. However, the identification of distinct subgroups of type 2 diabetes might also be necessary before pharmacogenetic studies can be successfully used for a stratified prescription of novel glucose-lowering drugs.
Keywords: Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide-1 receptor agonists; Pharmacogenetics; Precision medicine; Review; Sodium–glucose cotransporter 2 inhibitors; Type 2 diabetes.
Similar articles
-
Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.JAMA Netw Open. 2021 Feb 1;4(2):e2035792. doi: 10.1001/jamanetworkopen.2020.35792. JAMA Netw Open. 2021. PMID: 33523188 Free PMC article.
-
Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.J Manag Care Spec Pharm. 2021 Apr;27(4):435-443. doi: 10.18553/jmcp.2021.27.4.435. J Manag Care Spec Pharm. 2021. PMID: 33769857 Free PMC article.
-
Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.Clin Ther. 2017 Dec;39(12):2438-2447. doi: 10.1016/j.clinthera.2017.10.016. Epub 2017 Nov 22. Clin Ther. 2017. PMID: 29174215
-
Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.Clin Res Hepatol Gastroenterol. 2022 Aug-Sep;46(7):101970. doi: 10.1016/j.clinre.2022.101970. Epub 2022 Jun 1. Clin Res Hepatol Gastroenterol. 2022. PMID: 35659603
-
[Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].Ned Tijdschr Geneeskd. 2019 Jan 14;163:D2962. Ned Tijdschr Geneeskd. 2019. PMID: 30676706 Review. Dutch.
Cited by
-
Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through microRNA regulation linked to glucagon-like peptide-1 receptor agonists.Diabetol Metab Syndr. 2025 Jan 10;17(1):13. doi: 10.1186/s13098-025-01581-3. Diabetol Metab Syndr. 2025. PMID: 39794819 Free PMC article. Review.
-
Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations.Diabetes Metab Syndr Obes. 2023 Nov 16;16:3669-3689. doi: 10.2147/DMSO.S390752. eCollection 2023. Diabetes Metab Syndr Obes. 2023. PMID: 38028995 Free PMC article. Review.
-
The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus.Endocrine. 2025 Jan;87(1):73-78. doi: 10.1007/s12020-024-04007-8. Epub 2024 Aug 23. Endocrine. 2025. PMID: 39179734
-
Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response.Mol Biol Rep. 2023 Nov;50(11):9637-9647. doi: 10.1007/s11033-023-08836-0. Epub 2023 Oct 11. Mol Biol Rep. 2023. PMID: 37819499 Review.
-
Determinants in Tailoring Antidiabetic Therapies: A Personalized Approach.Glob Med Genet. 2022 Jun 13;9(2):63-71. doi: 10.1055/s-0041-1741109. eCollection 2022 Jun. Glob Med Genet. 2022. PMID: 35707783 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous